{"name":"Amarin Neuroscience Ltd","slug":"amarin-neuroscience-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ethyl-EPA (Miraxion™)","genericName":"Ethyl-EPA (Miraxion™)","slug":"ethyl-epa-miraxion","indication":"Hypertriglyceridemia (elevated triglycerides)","status":"phase_3"}]}],"pipeline":[{"name":"Ethyl-EPA (Miraxion™)","genericName":"Ethyl-EPA (Miraxion™)","slug":"ethyl-epa-miraxion","phase":"phase_3","mechanism":"Ethyl-EPA is an ethyl ester of eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism through omega-3 fatty acid supplementation.","indications":["Hypertriglyceridemia (elevated triglycerides)","Cardiovascular risk reduction in patients with elevated triglycerides"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}